Ltd Nirland Sells 333,177 Shares of Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Stock

by · The Cerbat Gem

Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) major shareholder Ltd Nirland sold 333,177 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $0.10, for a total value of $33,317.70. Following the transaction, the insider now directly owns 9,900,000 shares of the company’s stock, valued at approximately $990,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Ltd Nirland also recently made the following trade(s):

  • On Monday, September 30th, Ltd Nirland sold 1,016,823 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.12, for a total transaction of $122,018.76.

Conduit Pharmaceuticals Stock Performance

Shares of CDT opened at $0.10 on Friday. Conduit Pharmaceuticals Inc. has a fifty-two week low of $0.10 and a fifty-two week high of $8.75. The firm’s 50-day simple moving average is $0.15 and its two-hundred day simple moving average is $1.58.

Conduit Pharmaceuticals (NASDAQ:CDT – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.07) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Berenberg Bank raised shares of Conduit Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th.

View Our Latest Research Report on Conduit Pharmaceuticals

Conduit Pharmaceuticals Company Profile

(Get Free Report)

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

Further Reading